Mitsubishi UFJ Trust & Banking Corp Reduces Stock Position in Royalty Pharma plc (NASDAQ:RPRX)

Mitsubishi UFJ Trust & Banking Corp cut its holdings in Royalty Pharma plc (NASDAQ:RPRX) by 6.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,869,142 shares of the biopharmaceutical company’s stock after selling 137,164 shares during the period. Mitsubishi UFJ Trust & Banking Corp owned about 0.32% of Royalty Pharma worth $47,682,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Keene & Associates Inc. raised its position in shares of Royalty Pharma by 1.9% during the 4th quarter. Keene & Associates Inc. now owns 19,420 shares of the biopharmaceutical company’s stock worth $495,000 after acquiring an additional 370 shares in the last quarter. Blue Trust Inc. raised its holdings in Royalty Pharma by 31.3% during the fourth quarter. Blue Trust Inc. now owns 1,579 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 376 shares in the last quarter. Sanctuary Advisors LLC lifted its position in shares of Royalty Pharma by 0.9% during the 4th quarter. Sanctuary Advisors LLC now owns 41,854 shares of the biopharmaceutical company’s stock worth $1,068,000 after buying an additional 388 shares during the last quarter. Arizona State Retirement System lifted its position in shares of Royalty Pharma by 0.5% during the 4th quarter. Arizona State Retirement System now owns 110,637 shares of the biopharmaceutical company’s stock worth $2,822,000 after buying an additional 537 shares during the last quarter. Finally, GAMMA Investing LLC boosted its holdings in shares of Royalty Pharma by 31.4% in the 4th quarter. GAMMA Investing LLC now owns 2,471 shares of the biopharmaceutical company’s stock valued at $63,000 after buying an additional 590 shares in the last quarter. 54.35% of the stock is owned by hedge funds and other institutional investors.

Royalty Pharma Stock Up 0.0 %

Shares of NASDAQ:RPRX opened at $33.76 on Wednesday. Royalty Pharma plc has a 1-year low of $24.05 and a 1-year high of $34.20. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.44 and a quick ratio of 1.44. The stock has a market cap of $19.46 billion, a P/E ratio of 23.28, a P/E/G ratio of 2.31 and a beta of 0.47. The firm has a fifty day moving average price of $32.40 and a 200 day moving average price of $28.78.

Royalty Pharma (NASDAQ:RPRX) last announced its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, topping the consensus estimate of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. Sell-side analysts predict that Royalty Pharma plc will post 4.49 EPS for the current year.

Royalty Pharma Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, March 10th. Shareholders of record on Friday, February 21st were paid a $0.22 dividend. This is an increase from Royalty Pharma’s previous quarterly dividend of $0.21. This represents a $0.88 annualized dividend and a dividend yield of 2.61%. The ex-dividend date of this dividend was Friday, February 21st. Royalty Pharma’s dividend payout ratio (DPR) is 60.69%.

Wall Street Analysts Forecast Growth

Separately, TD Cowen raised shares of Royalty Pharma to a “strong-buy” rating in a research report on Tuesday, December 24th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Royalty Pharma currently has a consensus rating of “Buy” and an average target price of $41.60.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.